Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Porr, Valneva (22/01/2025)

26.01.2025

Porr: German rail technology company Vossloh AG said on Wednesday that it has awarded an order from Austrian construction group PORR as part of the British high-speed rail project High Speed 2 (HS2). Vossloh will supply rail fastening systems for the slab track on the line between London and Birmingham for the end customer HS2 Ltd. The order has a volume of over €30 million and covers the period from 2025 to 2027.
Österreichische Post: weekly performance: 0.34%

Valneva: Austrian/French Valneva today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the fourth quarter of 2025, with the objective to extend the product label to this age group.
Valneva: weekly performance: 9.65%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/01/2025)


Partners









latest 21st Austria

21st Austria weekly - Porr, Valneva (22/01/2025)


26.01.2025, 1143 Zeichen



Porr: German rail technology company Vossloh AG said on Wednesday that it has awarded an order from Austrian construction group PORR as part of the British high-speed rail project High Speed 2 (HS2). Vossloh will supply rail fastening systems for the slab track on the line between London and Birmingham for the end customer HS2 Ltd. The order has a volume of over €30 million and covers the period from 2025 to 2027.
Österreichische Post: weekly performance: 0.34%

Valneva: Austrian/French Valneva today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the fourth quarter of 2025, with the objective to extend the product label to this age group.
Valneva: weekly performance: 9.65%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/01/2025)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

BörseGeschichte Podcast: Max Otte vor 10 Jahren zum ATX-25er




 

Bildnachweis

Aktien auf dem Radar:voestalpine, AT&S, Andritz, RHI Magnesita, Austriacard Holdings AG, Pierer Mobility, Rosgix, Addiko Bank, CA Immo, Rosenbauer, FACC, Lenzing, OMV, EVN, Mayr-Melnhof, Wolford, Zumtobel, Gurktaler AG Stamm, Gurktaler AG VZ, Polytec Group, RBI, VIG, Wienerberger, Amag, UBM, Palfinger, EuroTeleSites AG, Oberbank AG Stamm, BKS Bank Stamm, Josef Manner & Comp. AG, SW Umwelttechnik.


Random Partner

Bechtle
Bechtle bietet Technologiekonzepte und umfassende IT-Lösungen für die digitale Transformation. Vom vollständigen IT-Arbeitsplatz über Datacenter und Multi-Cloud-Lösungen bis hin zu IT-Security und Künstliche Intelligenz entwickeln wir zukunftsfähige IT-Architekturen.

>> Besuchen Sie 61 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten